Trained on over five million spine MRI scans, the RAI software reportedly facilitates rapid pathology detection and enhanced consistency with disc measurement.
The Food and Drug Administration (FDA) has granted 510(k) clearance for RAI, an artificial intelligence (AI)-enabled software for spine magnetic resonance imaging (MRI) that may foster improved detection of abnormal findings and degenerative pathology.
Currently utilized by over 300 radiologists worldwide, the RAI software (Remedy Logic) offers automated segmentation and disc measurements that may reduce reading time for radiologists. The software also flags incidental findings, identifies abnormalities, and provides concise summaries for pathology detection, according to Remedy Logic.
The company noted that RAI, which will be showcased at the upcoming Radiological Society of North American (RSNA) 2004 Annual Meeting in Chicago, has been trained with over five million spine MRI scans.
“This achievement (FDA clearance) underscores our commitment to improving efficiency for radiologists for improved safety for patients and completeness and objectivity for referring physicians. who have been left behind by innovation, while addressing the critical issue of spine MRI volumes outpacing available radiologists,” noted Andrej Rusakov, the CEO of Remedy Logic.
New Study Examines Short-Term Consistency of Large Language Models in Radiology
November 22nd 2024While GPT-4 demonstrated higher overall accuracy than other large language models in answering ACR Diagnostic in Training Exam multiple-choice questions, researchers noted an eight percent decrease in GPT-4’s accuracy rate from the first month to the third month of the study.
FDA Grants Expanded 510(k) Clearance for Xenoview 3T MRI Chest Coil in GE HealthCare MRI Platforms
November 21st 2024Utilized in conjunction with hyperpolarized Xenon-129 for the assessment of lung ventilation, the chest coil can now be employed in the Signa Premier and Discovery MR750 3T MRI systems.
FDA Clears AI-Powered Ultrasound Software for Cardiac Amyloidosis Detection
November 20th 2024The AI-enabled EchoGo® Amyloidosis software for echocardiography has reportedly demonstrated an 84.5 percent sensitivity rate for diagnosing cardiac amyloidosis in heart failure patients 65 years of age and older.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.